Dyne Therapeutics’ stock sees record rally, but one analyst says it could still climb a lot further, after a rival got bought ...
I agree to the Terms of Use , Privacy Notice and Cookie Notice. I agree to the Terms of Use , Privacy Notice and Cookie ...
Novartis is buying Avidity Biosciences in an all-cash deal valued at $12 billion to access Avidity's experimental treatments for neuromuscular diseases.
TipRanks on MSN
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...
With U.S. stock markets set to open in two hours, Avidity Biosciences Inc. (RNA) was up 43.6% in pre-market trading, and BridgeBio Pharma Inc. (BBIO) was up 10.6%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback